CC
DRUG

Commodore Capital’s Bright Minds Biosciences DRUG Stock Holding History

Commodore Capital’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,851
Closed -$1.47M – 39
2025
Q4 		$1.47M Sell
18,851
-481,149
-96% -$32.2M 0.1% 33
2025
Q3 		$30.3M Hold
500,000
– – 1.48% 24
2025
Q2 		$13.1M Hold
500,000
– – 0.92% 25
2025
Q1 		$18M Hold
500,000
– – 1.33% 20
2024
Q4 		$18M Buy
+500,000
New +$17.6M 1.32% 21

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Commodore Capital's DRUG Position: Q1 2026 in Review

Commodore Capital sold out of Bright Minds Biosciences (DRUG) in Q1 2026, closing a stake of 18,851 shares — an estimated $1.47M sold.

Commodore Capital first reported a position in DRUG in Q4 2024 and held it in 5 quarters. The position peaked at $30.3M in Q3 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Commodore Capital reported no remaining Bright Minds Biosciences position as of Q1 2026 after selling out during the quarter.
  • Commodore Capital sold 18,851 Bright Minds Biosciences shares in Q1 2026, an estimated $1.47M.
  • Commodore Capital first reported a position in Bright Minds Biosciences in Q4 2024 and held it in 5 quarters.
  • Commodore Capital's Bright Minds Biosciences position peaked at $30.3M in Q3 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.